Background: The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < 10 g/m 2 show remissions when exposed to highdose ifosfamide (HDI) (i.e., doses > 10 g/m 2 ), which supports a dose-response relationship for this drug. Because of a lack of first-line studies in adult STS patients, we decided to test the activity and toxicity of HDI in a phase II trial.
Introduction
Only oxazaphosphorines and anthracyclines have shown consistent and reproducible activity against soft-tissue sarcomas (STS) of the adult. First-line therapy with doxorubicin yields a response rate of 17% to 27% [1, 2] , and studies with ifosfamide (IFOS) conducted in previously treated patients with doses < 10 g/m 2 (standarddose ifosfamide, SDI) showed a remission rate of 18% to 38% [3] [4] [5] . Pharmacokinetic studies indicate that the schedule of administration may be significant in IFOS therapy. When the dose is fractionated over five days, pharmacokinetic parameters determined on day 5 compared with those obtained on day 1 show a decrease in the AUC and in the elimination half-life of IFOS, with an increase in serum values of both maximal concentration and AUC of active and inactive IFOS metabolites [6] [7] [8] . These data theoretically support the hypothesis that divided IFOS dosing enhances the activity of the drug and may modify its toxicity.
When total IFOS dose was fractionated over four to five days and administered in a continuous or short infusion, the maximum tolerable dose was 85 mg/kg/day (approximately 3.5 g/m 2 /day) [9] or 18 g/m 2 [10] , with hematologic, renal and C.N.S. as dose-limiting toxicities. Studies conducted at doses of 12 to 14 g/m 2 (highdose ifosfamide, HDI) induced remissions in patients who had progressed to SDI, disclosing a dose-response effect for this drug [11, 12] . After completion of a pilot study [13] based on the report by Rosen et al. [14] , we decided to initiate a phase II clinical trial to determine the activity and toxicity of IFOS at 14 g/m 2 administered by CI over six days as first-line therapy in patients with advanced STS.
Patients and methods
Criteria of inclusion: histologic diagnosis of STS, locally advanced or metastatic disease, age between 15 and 75 years (later amended to 65 years), no prior chemotherapy including adjuvant, bidimensionally measurable disease progressing in the preceding four weeks, performance status (WHO) «J2, leukocytes >4,000/mm 3 , platelets > 100,000/mm 3 , serum creatinine <1.5 mg/dl, creatinine clearance >60 ml/min, total bilirubin > 1.5 mg/dl, and albumin >30 g/1. The study protocol was approved by the respective local Ethics Committees and informed written consent was obtained.
Patients received IFOS 14 g/m 2 plus Mesna 7 g/m 2 by continuous i.v. infusion over six days every four weeks. An initial dose of IFOS 2 g/m 2 plus Mesna 1 g/m 2 in 1,000 ml NS over two hours was followed by IFOS 2 g/m 2 plus Mesna 1 g/m 2 in 1,000 ml NS by CI over 24 hours for six consecutive days, with three doses of Mesna 600 mg/m 2 every six hours given at the end of the infusion. All patients received sodium bicarbonate 40 mEq/day from day 1-6. No dose reduction was allowed and cycles were repeated every 28 days if leukocytes >3,000/mm 3 , granulocytes 5; 1,000/mm 3 and platelets 5= 100,000/mm 3 ; otherwise, the cycle was delayed until these values were reached. After one episode of neutropenic fever, or if there was no hematologic recovery by day 28, granulocyte-macrophage colony-stimulating factor (GM-CSF, molgramostin) was systemically administered during subsequent cycles, starting on day 7, at 5 ug/kg/day for 10 consecutive days. All patients received prophylactic antiemetic therapy with dexamethasone and anti-HT 3 .
A complete CBC was performed weekly, with biweekly blood chemistry, creatinine clearance and microscopic examination of the urine. Evaluable lesions were measured every eight weeks WHO criteria were followed to evaluate response [15] , and in the absence of rapid progression two cycles were required to evaluate antitumor activity. Any objective remission had to be confirmed at least four weeks later and was externally reviewed. Rapid progression comprised the appearance of new lesions or an increase in any measurable disease > 50% after one cycle. All patients receiving at least one cycle were considered evaluable for toxicity, and the cycles with weekly CBC were assessable for hematologic toxicity. Common Toxicity Criteria of the NCI were applied. The dose intensity per cycle was calculated by dividing the dose administered (g/m 2 ) by the interval (weeks) between cycles, and the relative dose intensity was the ratio between the dose intensity per cycle and the projected dose intensity. From February 1995 to January 1997, 48 patients entered the trial. One patient was found ineligible and excluded from all analyses. The main characteristics of the 47 eligible and evaluable patients are listed in Table 1 . Leimyosarcomas originated in the retroperitoneum (six), uterus (five), small intestine (three), limbs (two), trunk (one) or the ovary (one). In 17 patients the primary tumor was the only site of measurable disease, 12 had both the primary tumor and metastasic disease, and 18 had only metastases. Nine patients had received prior radiotherapy to hematopoietic areas.
Results

Patient characteristics
Treatment
A total of 168 cycles were administered (six ambulatory), with a median of two per patient (range one to seven). Only one cycle was administered to each of three patients, one with rapidly progressive disease, one who died of a pulmonary thromboembolism on day 12, and a third with a decrease in creatinine clearance to 39 ml/min. The latter patient received a second cycle at a reduced dose, and presented neutropenic fever on day 7 followed by sepsis that caused his death, considered a toxic one, on day 14. The last two patients were not evaluable for antitumor activity. The median IFOS dose delivered per cycle was 14 g/m 2 (range 8.23-14.87), with more than 90% of the projected dose given in 93% of cycles. Eleven cycles were delayed because of toxicity, 15 for reasons unrelated to therapy, and the median cycle interval was four weeks (range three to 6.5). The median IFOS dose intensity (g/m 2 / week) was 3.5 (range 2.06-4.0), and the relative dose intensity was at least 90% in 83% of cycles. GM-CSF was prescribed to 28 patients (60%) in 68 cycles due to 
Figures represent number of cycles with the event.
neutropenic fever (24) , delay in hematologic recovery (three), protocol violation (one) or prior toxicity (40).
Hematologic toxicity
Forty-six patients and 158 cycles were evaluable for toxicity (Table 2 ). In 27 cycles (17%), hemoglobin values were lower than 8.0 g/dl and in 32 cycles patients required transfusions. Grade 4 leukopenia was noted in 76% of patients in 80 cycles; 80% in 91 cycles had grade 4 neutropenia, and grade 4 thrombocytopenia occurred in eight patients (11 cycles), with eight patients/cycles receiving platelet support. The median nadir of the three hematologic series occurred on day 13. The absolute nadir values of leukocytes and granulocytes and the mean time to recovery from aplasia were not influenced by GM-CSF administration. The median time to attainment of the required pretherapy values (i.e., leukocyteŝ 3,000/mm 3 , granulocytes ^ 1,000/mm 3 and platelets > 100,000/mm 3 ) was 19.5 days (range 12-30) and 21 days (range 13-38), respectively, in cycles with and without GM-CSF. Those values were observed in 90% of all cycles on day 27, and in 80% of cycles with GM-CSF on day 21.
Nonhematologic toxicity
Grade 3 nausea occurred in 13 patients and 17 cycles, and grade 4 vomiting in one (Table 2) . Twenty-three patients had grade 2-3 anorexia in 40 cycles, and 10 patients suffered grade 3 asthenia in 13 cycles. Alopecia occurred in all patients.
Transient increases in serum creatinine to values lower than 1.5 mg/dl (i.e., always within normal range) were observed in seven cycles, and to values between 1.5 and 1.8 mg/dl in three cycles, always associated with proteinuria or glycosuria. There were no episodes of acute renal failure. A creatinine clearance of 39 ml/min was observed in one patient, and values between 40 and 60 ml/min were detected in 13% of assessable cycles. Complete blood chemistries were not available from all cycles and values of sodium below 130 mEq/1 were observed in 5% of assessable cycles, potassium below 3 mEq/1 in 5%, calcium below 2,1 mEq/1 in 17%, phosphorus between 1,86 and 2,47 mg/dl in 17% and below 1,86 mg/dl in 20%, magnesium between 1,6 to 1,3 mEq/1 in 55% and below 1,3 mEq/1 in 2%, and bicarbonate below 20 mEq/1 in 19%. Grade 2 proteinuria was observed in four patients, glycosuria higher than 0,3 g/24 hours was detected in 11 patients and 28 cycles, always accompanied by proteinuria. Most of these changes had reversed by day 28 of the cycle. Microscopic hematuria was observed in 13 patients (32%) and 22 cycles. Gross hematuria was observed in two patients whose tumors infiltrated or compressed the urinary tract, in one patient concomitant with a low platelet count and in one patient who had presented microscopic hematuria and intense dysuria in the previous cycle. One patient had a hemorrhagic cystitis after the first cycle requiring packed red cell transfusions and additional doses of Mesna amounting to 315%. This patient received five additional cycles with Mesna at 100% of the IFOS dose without further problems. Five patients had dysuria in 12 cycles.
Fifteen patients in 20 cyles reported visual hallucinations, associated in three of them with difficulties in focusing, in another three with mild somnolence (one was taking oral morphine), in one with blurred vision and in another with a mild unilateral decrease in visual acuity. One patient with hallucinations and moderate somnolence during her third cycle received i.v. methylene blue that reversed the episode [16] ; she was withdrawn from the study with stable disease. None of the other patients in the study received either prophylactic or therapeutic treatment with methylene blue. Seven patients had mild to moderate somnolence in nine cycles, one patient noted resting tremor with moderate sensory loss in two cycles, and the exact type of neurotoxicity was not specified in three patients. One patient in five cycles noted difficulty in focusing. After 13 cycles five patients had mild paresthesias. One suffered a painful neuropathy of moderate intensity in two cycles and was treated with carbamazepine. These sensorial toxicities were reported to have occurred in the lower extremities, were associated with hallucinations during the infusion of IFOS and persisted after discontinuation of the therapy.
There were 35 episodes of neutropenic fever, 12 in patients receiving prophylactic GM-CSF. Twenty-two patients on 31 occasions were admitted to the hospital because of neutropenic fever, and five additional patients due to complications of the primary tumor (three), pneumonia (one) or oral candidiasis causing severe dysphagia (one). During the study there were eight documented incidents of sepsis, with one septic death, and 29 patients in 40 cycles required antibiotic support. One patient developed a myelodysplasic syndrome which transformed into acute leukemia after a cumulative dose of 151.2 g IFOS. 
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Response to therapy and evolution
One of 45 patients assessable for antitumor activity had a complete remission, 16 had partial remissions, 17 showed stable disease and 11 progressed to therapy. The overall response rate was 37.7% (95% CI: 25.5-50%). The patient in complete clinical remission and five patients in partial remission achieved documented pathologic complete remission (pCR). Tables 3 and 4 present response rate by histologic subtype and tumor site, respectively. Gynecologic (one PCR, one PR, two NC, two PD) or somatic (one PCR, two PD) LMS responded, but those originating in the retroperitoneum (three NC, three PD) or the small intestine (two NC, one PD) did not. The remission rate was not influenced by age, sex, histologic grade, performance status or GM-CSF administration. Objective activity was noted after a median of two cycles (range two to five); 14 of 17 remissions were observed after two cycles and two after three cycles. Nine patients, four in partial remission and five with stable disease, either refused therapy or were removed from the trial due to excessive toxicity after receiving a median of three cycles (range one to six). The reasons were: asthenia in four patients, and one each with two consecutive episodes of sepsis, two cycles with grade 4 platelet toxicity associated with septic episodes, neurocortical toxicity grade 3, grade 4 vomiting, and a treatment-related decrease in performance status. Twenty patients abandoned the study due to progressive disease, and 16 patients stopped treatment to undergo surgery (one CR, nine PR, five SD, one PD) after receiving a median of four cycles (range two to six). The lesions in 14 patients were completely resected with no viable tumor found in six, eight patients progressed a median of seven months after surgery and six had no evidence of disease at a median of 16.8 months (range [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The duration of complete and partial remissions was influenced by the surgery performed, and the data are not presented. Excluding four patients with a successful resection of the disease, the median duration of stable disease was six months (range 2.80-16.5) and the median time to progression in 47 patients was six months. The median follow-up is 19 months (range 12-36+), 27 patients have died (24 of disease), one was lost to follow-up, and eight of 19 surviving patients have no evidence of disease. The median overall survival time was 18.53 months (range 0.4-36+).
Discussion
First-line administration of IFOS at a dose of 14 g/m 2 by CI over six days yielded a response rate of 37.7% in 45 evaluable adult patients with advanced STS. Worthy of note is the 13% rate of pathologic complete remissions found and the additional 38% of patients with stable disease for a median of 6 months. Second-line therapy with SDI or HDI induced a clinical complete response rate that varied from 0% to 15% [3, 5, 17, 18] and the overall objective activity encountered is within the range reported for HDI given either as first-or second-line therapy. In the only trial that has included nonpretreated patients, a remission rate of 50% was found in 20 evaluable patients treated with doses of 12.5 to 15 g/m 2 delivered by four-hour infusion for five days [19] . Threeand four-day CI schedules of HDI administered to patients pretreated with anthracyclines [18] , or with anthracyclines and SDI [17, 20] , obtained a 19% to 40% response rate. While the results of pharmacokinetic studies indicate that IFOS is probably best administered in divided doses over several days [6] [7] [8] , whether the daily dose should be given in a continuous or in a short infusion remains an unresolved issue, although available data from nonrandomized studies point to a higher activity of short infusions [5, 18, 21] .
The design of the study did not allow dose reductions and the selected dose of 14 g/m 2 caused considerable toxicity. It seems unlikely that the dose intensity achieved could be increased, considering the criteria applied for the administration of GM-CSF and that in only 80% of GM-CSF cycles minimum pretherapy hematologic values were reached on day 21. However, systemic administration of G-CSF allowed doses of 14 g/m 2 to be repeated every three weeks [20] , although the report does not include the dose intensity actually delivered. Fifty-four per cent of our patients suffered one or more episodes of neutropenic fever, 34% of which occurred in patients under prophylactic GM-CSF treatment, a figure comparable to that observed in STS patients treated with HDI receiving granulocyte-stimulating factors [18, 22] . Fifty percent of our cycles caused grade 4 leukopenia while, in pretreated patients and despite the routine administrarion of prophylactic G-CSF, IFOS induced WBC toxicity grade 4 in all cycles delivered at doses higher than 12 g/m 2 [22] , or neutropenia grade 3-4 in at least 73% of cycles delivered at doses from 10 to 14 g/m 2 [18] . IFOS also causes thrombocytopenia grades 3-4 in about 70% of patients treated at doses higher than 14 g/m 2 administered over four days or less [10, 18, 22] . Of note are four reports with limited information, where grade 4 platelet toxicity was either mild or not observed after IFOS doses of 12 to 17.5 g/m 2 delivered by short or continuous infusion over five to seven days [9, 19, 23, 24] . Whether or not the hematologic toxicity caused by HDI can be influenced by the administration schedule can only be clarified in appropriately designed studies.
The schedule selected did not lead to severe renal toxicity. Prevention of renal acidosis by administration of sodium bicarbonate (40 mEq/day) and the rate of infusion selected probably had a protective effect on kidney function. This is confirmed by the results of other HDI trials in which acute renal failure (ARF) episodes were uncommon when higher amounts of sodium bicarbonate or acetate were administered [14, 18, 24, 25] . In contrast, four irreversible ARF episodes and nine prolonged tubular dysfunctions were observed in 40 patients treated with 12 g/m 2 IFOS delivered by CI over three days when no prophylactic measures for renal acidosis were instituted [17] . Further data suggest that sodium bicarbonate might not be necessary when HDI is given by CI at daily doses ^3.5 g/m 2 [20] . Although analytical data are incomplete, we observed signs of tubular and glomerular dysfunction in up to 60% of patients. The intensity of those changes, however, was lower than those reported with equivalent IFOS doses infused at a higher rate [18] , a finding already observed with SDI [5] .
Treatment was stopped due to hallucinations and moderate somnolence in one patient. The visual hallucinations that our patients reported in up to 12% of cycles did not cause discomfort and, in our opinion, they should not be considered grade 3 toxicity and should not determine the interruption of therapy. However, because they may herald the appearance of a more severe toxicity, a closer surveillance for CNS symptoms must be instituted and a careful evaluation of concomitant medication performed. However, administration of prophylactic methylene-blue [16] does not seem to be necessary in those patients who had hallucinations and continue with HDI therapy. Renal and CNS [27] toxicities, often combined, follow a more unpredictable pattern than the hematologic toxicity and have been observed in adult patients with all schedules and doses of IFOS. Both total dose and rate of infusion can contribute to renal and CNS toxicities [5, 10, 22, 24, 26, 28] , suggesting that there is a renal threshold for disposal of the drug and its metabolites.
Asthenia grade 3 was reported by 22% of our patients and 64% could not carry out normal activity. Nine patients (20%) stopped therapy because of treatmentrelated side effects and the fact that only six patients tolerated more than five cycles underscores the overall toxicity caused by this HDI schedule. Since response to therapy occurs early in therapy, this regimen is more suitable for inducing a rapid remission than for prolonged therapy. Although IFOS activity against STS has been demonstrated at all dose levels, to obtain the maximum antitumor effect this drug should probably be administered in doses ^12 g/m 2 . However, before widespread administration of HDI, different schedules should be compared to determine which one has the best therapeutic index. The combination of HDI with an anthracycline, the next logical step, is presently under evaluation in different centers.
